A recently published meta-analysis of 12 trials by Sajan Shrestha [24] demonstrated that IGU monotherapy has similar ACR 20 and HAQ, and better disease state, lower CRP level and ESR compared with other DMARDs therapy, which is basically consistent with our findings, indicating that IGU may be considered a potential alternative to MTX to treat RA. The gene discussed is CRP; the disease is rheumatoid arthritis.